Why carry out this study?

In the SUSTAIN Program, once-weekly (ow) subcutaneous semaglutide, the most recent glucagon-like peptide receptor agonist (GLP-1RA) available in Italy, has shown safety and clinically relevant improvements in glycemic control and body weight versus a wide range of comparators in people with type 2 diabetes (T2D).

Real-world evidence (RWE) data generation is crucial not only to confirm safety and effectiveness of this drug in routine clinical practice but also to complement evidence from randomized clinical trials.

What was learned from the study?

This study confirms the effectiveness and tolerability of semaglutide in real-world clinical practice, without any new safety concerns.

Patients receiving semaglutide experienced statistically significant and clinically relevant glycemic reduction and obesity index improvements. These results are documented not only in GLP-1RA naïve patients, but also in patients already treated with other GLP-1RAs.